Vivo Capital Leads $50M Series B Round In Chinese CRO Firm dMed Biopharmaceutical

dMed Biopharmaceutical Co., Ltd., a Chinese full service Clinical Contract Research Organization (CRO), announces on Wednesday that it has completed nearly US$50 million in a series B financing round. The round is led by healthcare-focused investment firm Vivo Capital, with participation from Chinese venture capital firm Legend Capital, Chinese Qiming Venture Partners and Shanghai-based biomedical […]

Vivo Capital Leads $50M Series B Round In Chinese CRO Firm dMed Biopharmaceutical comes originally from China Money Network. All Rights Reserved.

Read the original article: China Money Network